ATE451362T1 - Salze von liponsaürederivaten und deren verwendung bei der behandlung von krankheiten - Google Patents

Salze von liponsaürederivaten und deren verwendung bei der behandlung von krankheiten

Info

Publication number
ATE451362T1
ATE451362T1 AT04077618T AT04077618T ATE451362T1 AT E451362 T1 ATE451362 T1 AT E451362T1 AT 04077618 T AT04077618 T AT 04077618T AT 04077618 T AT04077618 T AT 04077618T AT E451362 T1 ATE451362 T1 AT E451362T1
Authority
AT
Austria
Prior art keywords
diseases
salts
treatment
acid derivatives
liponic acid
Prior art date
Application number
AT04077618T
Other languages
English (en)
Inventor
Zuzana Zachar
Paul M Bingham
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Application granted granted Critical
Publication of ATE451362T1 publication Critical patent/ATE451362T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AT04077618T 1998-10-26 1999-10-26 Salze von liponsaürederivaten und deren verwendung bei der behandlung von krankheiten ATE451362T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10562898P 1998-10-26 1998-10-26

Publications (1)

Publication Number Publication Date
ATE451362T1 true ATE451362T1 (de) 2009-12-15

Family

ID=22306916

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04077618T ATE451362T1 (de) 1998-10-26 1999-10-26 Salze von liponsaürederivaten und deren verwendung bei der behandlung von krankheiten
AT99956698T ATE277034T1 (de) 1998-10-26 1999-10-26 Liponsaürederivate und deren verwendung bei der behandlung von krankheiten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99956698T ATE277034T1 (de) 1998-10-26 1999-10-26 Liponsaürederivate und deren verwendung bei der behandlung von krankheiten

Country Status (12)

Country Link
US (2) US6331559B1 (de)
EP (3) EP1486495B1 (de)
JP (2) JP4728481B2 (de)
AT (2) ATE451362T1 (de)
AU (1) AU774362B2 (de)
BR (1) BR9914789A (de)
CA (1) CA2348998C (de)
DE (2) DE69941800D1 (de)
ES (2) ES2340488T3 (de)
IL (2) IL142824A0 (de)
MX (1) MXPA01004152A (de)
WO (1) WO2000024734A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
EP1133487B1 (de) * 1998-11-25 2004-09-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antioxidationsmittel
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
IT1312060B1 (it) * 1999-04-09 2002-04-04 Antibioticos Spa Uso dell'acido alfa lipoico nel trattamento antimetastatico.
ES2162586B1 (es) * 1999-11-25 2002-07-01 Moraleda Manuel Gomez Composicion que comprende aceites ozonizados y/o otros productos naturales y/o sinteticos ozonizados, y su empleo en composiciones farmaceuticas, cosmeticas, dieteticas o de suplementos alimentarios, en los campos humano y veterinario
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
EP1172110A3 (de) * 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
IT1319196B1 (it) * 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Sintesi dell'acido r(+)alfa-lipoico.
US7109362B2 (en) 2000-11-30 2006-09-19 Basf Aktiengesellschaft Process for the preparation of lipoic acid and dihydrolipoic acid
EP1371640B1 (de) * 2001-03-19 2009-10-28 Senju Pharmaceutical Co., Ltd. Neues a-liponsäurederivat und dessen verwendung
US6936641B2 (en) * 2002-06-25 2005-08-30 Johnson & Johnson Vision Care, Inc. Macromer forming catalysts
WO2004006859A2 (en) * 2002-07-16 2004-01-22 Sonus Pharmaceuticals, Inc. Platinum compound
KR100973450B1 (ko) * 2002-09-13 2010-08-02 유겐가이샤 오가 리서치 멜라닌 소거제
WO2004071458A2 (en) 2003-02-13 2004-08-26 Albert Einstein College Of Medicine Of Yeshiva University REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
US20040248982A1 (en) * 2003-06-09 2004-12-09 Dyer Gordon Wayne Use of compounds for the inhibition of proteins and UV protection
EP1651207A4 (de) * 2003-06-12 2008-10-01 Univ Colorado Systeme und verfahren zur behandlung von entzündlichen und proliferativen erkrankungen und wunden des menschen mit fettsäure-stoffwechsel-hemmern und/oder glykolytischen hemmern
US7510710B2 (en) * 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
CA2560059A1 (en) * 2004-03-15 2005-09-29 Sonus Pharmaceuticals, Inc. Platinum carboxylate anticancer compounds
US7582418B2 (en) * 2004-11-03 2009-09-01 Albion Laboratories, Inc. Antimicrobial chelates
WO2006116217A2 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of Colorado Therapeutic bifunctional compounds
AU2006242667A1 (en) * 2005-05-02 2006-11-09 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism and glycolysis inhibition
US20070225354A1 (en) * 2006-03-21 2007-09-27 Eric Marchewitz Use of dihydrolipoamide for enhancing physical performance
US8263653B2 (en) 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
AU2008242827B2 (en) * 2007-04-18 2014-06-05 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
KR101644192B1 (ko) * 2007-04-18 2016-07-29 코너스톤 파마슈티칼스, 인크. 리포산 유도체
WO2009105230A2 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
MX2010009673A (es) * 2008-03-04 2011-03-15 Robert Shorr Modulacion de la estructura, actividad y/o nivel de expresion enzimaticos.
SG10201608068SA (en) 2008-04-01 2016-11-29 Antipodean Pharmaceuticals Inc Compositions And Methods For Skin Care
WO2009123597A1 (en) * 2008-04-04 2009-10-08 Robert Shorr Pharmaceutical composition
CA2730773A1 (en) 2008-07-14 2010-01-21 Martha Karen Newell Methods and products for treating proliferative diseases
WO2010019225A1 (en) * 2008-08-15 2010-02-18 Robert Shorr Pharmaceutical composition
EP2350274B1 (de) 2008-10-21 2019-01-23 The General Hospital Corporation Zelltransplantation
FR2937867B1 (fr) 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
WO2010062381A1 (en) * 2008-11-28 2010-06-03 Robert Shorr Organelle-specific drug delivery
RU2011124739A (ru) * 2008-12-01 2013-01-10 Инваск Терапьютикс, Инк. Композиции, содержащие ингибиторы системы ренин-ангиотензин альдостерона и соединения липоевой кислоты, и их применение для лечения заболеваний, связанных с системой ренин-ангиотензин альдостерона
CN101787013B (zh) * 2009-01-22 2013-04-24 杭州民生药业有限公司 硫辛酰胺系列衍生物、制备方法及所述衍生物的制药用途
WO2010110887A1 (en) * 2009-03-24 2010-09-30 Robert Shorr Fatty acids
WO2010110771A2 (en) * 2009-03-25 2010-09-30 Frank Gibson Substituted thiol-containing alkyl fatty acids and process for synthesizing derivatives thereof
WO2011046583A1 (en) * 2009-09-11 2011-04-21 Robert Shorr Pharmaceutical exploitation of oxidative stress in transformed cells
FR2959668B1 (fr) * 2010-05-05 2012-07-13 Biorebus Association pharmaceutique contenant l'acide lipoique, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
WO2011138565A1 (fr) 2010-05-05 2011-11-10 Biorebus Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
WO2011143593A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
WO2011143590A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
WO2011146635A1 (en) * 2010-05-21 2011-11-24 North Texas Medical Associates Malignant neoplasm treatment protocol
BR112013002859B1 (pt) 2010-08-06 2020-10-06 The General Hospital Corporation D/B/A Massachusetts General Hospital Método e aparelho para tratamento de células
EP2934542A4 (de) * 2012-12-19 2016-08-10 Robert Shorr Pharmazeutische verbindungen
US9605012B2 (en) * 2013-01-17 2017-03-28 Garnett Mckeen Laboratory, Inc. Palladium-ruthenium-zinc-organo complexes and methods for their use in the treatment of inflammatory diseases
AU2014398233B2 (en) 2014-06-19 2019-11-28 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
ES2819175T3 (es) 2014-06-19 2021-04-15 Rafael Pharmaceuticals Inc Compuestos farmacéuticos
US10052305B2 (en) 2015-10-07 2018-08-21 Buck Institute For Research On Aging Lipoic acid and derivatives thereof for the treatment of cystinuria

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE362916C (de) 1921-08-13 1922-11-02 Eduard Duerr Abnehmbares Mikrometer fuer Schublehren
GB758897A (en) * 1953-10-19 1956-10-10 Merck & Co Inc Thio-substituted aliphatic carboxylic acids and their preparation
US2853497A (en) 1953-12-04 1958-09-23 Merck & Co Inc 6, 8-bis (hydrocarbon substituted mercapto) 5-hydroxycaprylic acids and delta-lactones thereof
US2975198A (en) * 1954-07-08 1961-03-14 Research Corp Lipoic acid intermediates
US2872458A (en) * 1954-12-30 1959-02-03 Merck & Co Inc Addition product of a metal hydrocarbon mercaptide with an alpha-halogamma-butyrolactone
JPS57123107A (en) 1981-01-26 1982-07-31 Pola Chem Ind Inc Cosmetic
DE3512911A1 (de) * 1985-04-11 1986-10-16 Degussa Ag, 6000 Frankfurt Verfahren zur herstellung von 1,2-dithiolan-3-pentansaeure (thioctsaeure)
DE3626116A1 (de) 1986-08-01 1988-02-11 Karl Thiel Thermostatische regeleinrichtung fuer heizungen bzw. heizaggregate
DE3629116A1 (de) * 1986-08-27 1988-03-10 Asta Pharma Ag Verfahren zur herstellung enantiomerenreiner r-(+)-(alpha)-liponsaeure und s-(-)-(alpha)-liponsaeure (thioctsaeure) sowie nonen- beziehungsweise mesylderivate als zwischenprodukte hierfuer
DE3900649A1 (de) 1989-01-11 1990-07-12 Boehringer Mannheim Gmbh Verfahren zur abloesung eines analyten von seinem bindeprotein
JPH03193758A (ja) * 1989-12-25 1991-08-23 Nisshin Oil Mills Ltd:The 新規γ―アミノ酪酸誘導体
DK0530446T3 (da) * 1991-07-05 1998-09-23 Asta Medica Ag Anvendelse af svovlholdige carboxylsyrer til bekæmpelse af pathophysiologisk betingede exitationsforstyrrelser
DE4137773A1 (de) * 1991-11-16 1993-05-19 Degussa Herstellung und verwendung von salzen der reinen enantiomere der (alpha)-liponsaeure
WO1994006794A1 (en) 1992-09-24 1994-03-31 National Institutes Of Health Aralkyl diazabicycloalkane derivatives for cns disorders
DE4310142A1 (de) * 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Immunologisch aktive Konjugate und ein Verfahren zu ihrer Herstellung
US5463093A (en) * 1993-11-26 1995-10-31 Garnett; Merrill Palladium complexes and methods for using same in the treatment of tumors or Psoriasis
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
DE4439477C2 (de) * 1994-11-08 1999-10-21 Asta Medica Ag Verwendung von R,S-(+/-)-alpha-Liponsäure, R-(+)-alpha-Liponäure, S-(-)-alpha-Liponsäure in reduzierter oder oxidierter Form oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung der diabetischen Mikroangiopathie
DE19601787C1 (de) * 1996-01-19 1997-07-24 Asta Medica Ag Herstellung und Verwendung von Salzen der 6,8-Bis(amidiniumthio)-octansäure
WO1998001440A2 (en) * 1996-07-05 1998-01-15 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
EP0855396A1 (de) * 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Metabolite von Thioctsäure und deren Verwendung
EP0979073A4 (de) * 1997-03-31 2004-04-07 Childrens Medical Center Nitrosylierung zur inaktivierung apoptotischer enzyme
AU728488B2 (en) * 1997-04-02 2001-01-11 Sankyo Company Limited Dithiolan derivatives, their preparation and their therapeutic effect
JPH11124379A (ja) * 1997-10-17 1999-05-11 Ss Pharmaceut Co Ltd ジチオリリデンアセトアミド誘導体
FR2777001B1 (fr) 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
US6204288B1 (en) * 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
US6387945B2 (en) * 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
US10562898B2 (en) 2016-02-05 2020-02-18 Ea Pharma Co., Ltd. Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity

Also Published As

Publication number Publication date
ATE277034T1 (de) 2004-10-15
US6951887B2 (en) 2005-10-04
US20020107234A1 (en) 2002-08-08
EP1486495A1 (de) 2004-12-15
CA2348998C (en) 2012-03-06
AU774362B2 (en) 2004-06-24
IL142824A0 (en) 2002-03-10
IL142824A (en) 2010-11-30
EP1124820A1 (de) 2001-08-22
JP5727721B2 (ja) 2015-06-03
MXPA01004152A (es) 2002-06-04
JP4728481B2 (ja) 2011-07-20
AU1324600A (en) 2000-05-15
WO2000024734A1 (en) 2000-05-04
DE69920497T2 (de) 2006-02-09
ES2340488T3 (es) 2010-06-04
JP2002528446A (ja) 2002-09-03
JP2010248203A (ja) 2010-11-04
EP1486495B1 (de) 2009-12-09
DE69941800D1 (de) 2010-01-21
EP2145883A1 (de) 2010-01-20
DE69920497D1 (de) 2004-10-28
BR9914789A (pt) 2001-10-02
US6331559B1 (en) 2001-12-18
ES2229790T3 (es) 2005-04-16
CA2348998A1 (en) 2000-05-04
EP1124820B1 (de) 2004-09-22

Similar Documents

Publication Publication Date Title
ATE451362T1 (de) Salze von liponsaürederivaten und deren verwendung bei der behandlung von krankheiten
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
CY1112845T1 (el) Παραγωγα της 1-δεοξυ-γαλακτονογιριμυκινης και η χρηση τους στη θεραπεια αθροιστικων λυσοσωμικων ασθενειων μεσω ενισχυσης της λυσοσωμικης α-γαλακτοσιδασης α
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
DE69711894D1 (de) Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung
DE3852374D1 (de) Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen.
DE69004081D1 (de) Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
DE69830336D1 (de) Ein kovalentes konjugat von clozapine und einer fettsäure und dessen verwendung zur behandlung von schizophrenie
ATE275608T1 (de) Behandlung von mineralfüllstoffen mit phosphaten, diese füllstoffe und deren verwendung
ATE460166T1 (de) Chinazolinderivate und ihre verwendung bei der behandlung von thrombocythämie
DE69519937D1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
DE69523654D1 (de) Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen
ATE336485T1 (de) Substituierte heterocyclen und deren verwendung in arzneimitteln
DE60036826D1 (de) Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
DE3789347D1 (de) 5-Substituierte Amino-4-hydroxy-pentansäure-Derivate und deren Verwendung.
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
ATE254128T1 (de) Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
DK205288D0 (da) Nitrifikationshaemmende middel
DE3876846D1 (de) Morpholinderivate und deren verwendung.
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties